Denmark-based foundation Novo’s quasi-corporate venturing unit has helped US-based healthcare company Tarsa Therapeutics raise $28m.
Novo was joined in the series B round on Friday by venture firm Foresite Capital, which led the round, as well as venture firms MVM Life Science Partners and Quaker Partners.
James Tananbaum, Foresite chief executive, joined Tarsa’s board. Tarsa is developing a drug for the prevention of postmenopausal osteoporosis. Tarsa secured exclusive global development and commercialisation rights (excluding China) for the drug from Unigene Laboratories in 2009. Unigene is also a part owner of Tarsa.
In 2011 the company raised $15m of a planned $24.5m financing, according to this Securities and Exchange Commission filing.
In 2009 the company raised $12m of a planned $24m financing. according to this filing.